ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.86% | 183.34% | 417.41% | 587.76% | 380.56% |
| Total Other Revenue | -- | -- | 305.56% | 406.67% | -100.00% |
| Total Revenue | 33.96% | 193.51% | 413.98% | 576.76% | 185.74% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 33.96% | 193.51% | 413.98% | 576.76% | 185.74% |
| SG&A Expenses | -18.43% | 0.03% | -28.12% | -13.20% | 68.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.20% | 46.38% | -1.05% | 27.82% | -3.79% |
| Operating Income | -8.51% | -19.11% | 59.60% | 12.94% | 22.21% |
| Income Before Tax | -68.19% | -49.96% | 64.34% | 12.49% | 56.60% |
| Income Tax Expenses | -100.00% | -- | -371.12% | -- | -- |
| Earnings from Continuing Operations | -68.03% | -51.10% | 66.63% | 12.46% | 56.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | -68.03% | -43.42% | 66.70% | 13.22% | 56.55% |
| EBIT | -8.51% | -19.11% | 59.60% | 12.94% | 22.21% |
| EBITDA | -8.10% | -20.15% | 65.23% | 15.44% | 22.43% |
| EPS Basic | -37.28% | -42.24% | 66.98% | 13.94% | 61.23% |
| Normalized Basic EPS | 10.47% | -10.18% | 64.79% | 18.12% | 46.47% |
| EPS Diluted | -37.28% | -43.29% | 67.37% | 13.94% | 61.23% |
| Normalized Diluted EPS | 10.47% | -10.18% | 64.79% | 18.12% | 46.47% |
| Average Basic Shares Outstanding | 22.42% | 0.84% | 0.90% | 0.85% | 12.08% |
| Average Diluted Shares Outstanding | 22.42% | 0.84% | 0.90% | 0.85% | 12.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |